At a Glance
- Share via
Other earnings, excluding one-time gains or charges unless noted, include:
* Biogen Inc. said third-quarter profit rose 10% to $68.4 million, or 44 cents a share, a penny better than estimates. Sales rose 12% to $233.7 million, led by an 18% jump in sales of Avonex, the world’s best-selling multiple sclerosis treatment. Avonex accounts for 80% of Biogen’s revenue.
* Rite Aid Corp. said losses from continuing operations more than doubled in its fiscal second quarter to $425 million, or $1.87 a share, from $154.4 million, or 60 cents, a year ago, swollen by debt-related charges, higher interest expense and increased store closings. Revenue rose 6% to $3.4 billion. Sales at stores open at least a year were up 9.9%, boosted by higher prescription sales. Rite Aid shares, which have tumbled 50% since July, fell 81 cents, or 20%, to close at $3.19 on the NYSE.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.